Menu
Articles
Source: SITEMAN Cancer Center, Julia Evangelou Strait, June 2021.
Source: BIOCENTURY Wugen: deploying memory NK cells against cancer AND TURNING ALLOGENEIC CAR T CELLS AGAINST T CELL MALIGNANCIES BY LAUREN MARTZ, …
Currently approved cellular therapies have been shown to effectively treat B-cell cancers, but there remains a significant unmet need for treating other cancers, including solid tumors.
BioWorld, David Ho, March 2021.
Technology Networks, Ryan Sullivan, Wugen, March 2021
St. Louis Business Journal, Nathan Rubbelke, March 2021
St. Louis Business Journal, Nathan Rubbelke, February 2021
Biospace, Kate Goodwin, January 2021
Latest News
— WU-NK-101 exhibited enhanced metabolic flexibility and resistance to tumor microenvironment immunosuppression relative to conventional …
ST. LOUIS, MO and SAN DIEGO, CA, June 1, 2022- Wugen, Inc., a clinical-stage biotechnology company …
ST. LOUIS, MO and SAN DIEGO, CA, May 12, 2022 –Wugen, Inc., a clinical-stage biotechnology …
Next in our story
Copyright © 2022 Wugen. All Rights Reserved.
a COGNEO design